Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells

被引:0
|
作者
M K Hasan
J Yu
L Chen
Bing Cui
G F Widhopf II
L Rassenti
Z Shen
S P Briggs
T J Kipps
机构
[1] Moores Cancer Center,
[2] University of California San Diego,undefined
[3] Section of Cell and Developmental Biology,undefined
[4] University of California San Diego,undefined
来源
Leukemia | 2017年 / 31卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
ROR1 (receptor tyrosine kinase-like orphan receptor 1) is a conserved, oncoembryonic surface antigen expressed in chronic lymphocytic leukemia (CLL). We found that ROR1 associates with hematopoietic-lineage-cell-specific protein 1 (HS1) in freshly isolated CLL cells or in CLL cells cultured with exogenous Wnt5a. Wnt5a also induced HS1 tyrosine phosphorylation, recruitment of ARHGEF1, activation of RhoA and enhanced chemokine-directed migration; such effects could be inhibited by cirmtuzumab, a humanized anti-ROR1 mAb. We generated truncated forms of ROR1 and found its extracellular cysteine-rich domain or kringle domain was necessary for Wnt5a-induced HS1 phosphorylation. Moreover, the cytoplamic, and more specifically the proline-rich domain (PRD), of ROR1 was required for it to associate with HS1 and allow for F-actin polymerization in response to Wnt5a. Accordingly, we introduced single amino acid substitutions of proline (P) to alanine (A) in the ROR1 PRD at positions 784, 808, 826, 841 or 850 in potential SH3-binding motifs. In contrast to wild-type ROR1, or other ROR1P→A mutants, ROR1P(841)A had impaired capacity to recruit HS1 and ARHGEF1 to ROR1 in response to Wnt5a. Moreover, Wnt5a could not induce cells expressing ROR1P(841)A to phosphorylate HS1 or activate ARHGEF1, and was unable to enhance CLL-cell motility. Collectively, these studies indicate HS1 plays an important role in ROR1-dependent Wnt5a-enhanced chemokine-directed leukemia-cell migration.
引用
收藏
页码:2615 / 2622
页数:7
相关论文
共 50 条
  • [41] Does CD5 have an effect on the expression of ROR1 in chronic lymphocytic leukemia (CLL)?
    Alsulami, H.
    Hallek, M.
    Kreuzer, K. A.
    ONKOLOGIE, 2011, 34 : 138 - 139
  • [42] SMALL MOLECULES TARGETING ROR1 INDUCE SPECIFIC KILLING OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS
    Moshfegh, A.
    Khan, S.
    Vagberg, J.
    Bystrom, S.
    Hojat-Farsangi, M.
    Mansouri, L.
    Sandin, A.
    Manesh, A. Danesh
    Osterborg, A.
    Mellstedt, H.
    HAEMATOLOGICA, 2012, 97 : 433 - 433
  • [43] High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia
    Emanuela M. Ghia
    Laura Z. Rassenti
    Michael Y. Choi
    Miguel Quijada-Álamo
    Elvin Chu
    George F. Widhopf
    Thomas J. Kipps
    Leukemia, 2022, 36 : 1609 - 1618
  • [44] High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia
    Ghia, Emanuela M.
    Rassenti, Laura Z.
    Choi, Michael Y.
    Quijada-Alamo, Miguel
    Chu, Elvin
    Widhopf, George F., II
    Kipps, Thomas J.
    LEUKEMIA, 2022, 36 (06) : 1609 - 1618
  • [45] Efficient Gene Delivery to Chronic Lymphocytic Leukemia (CLL) Cells with Microbubbles Bearing ROR1 Antibody
    Zhang, Suping
    Cui, Wenjin
    Mattrey, Robert
    Kipps, Thomas J.
    BLOOD, 2011, 118 (21) : 1232 - 1232
  • [46] Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells
    Hasan, Md Kamrul
    Rassenti, Laura Z.
    Widhopf, George F., II
    Kipps, Thomas J.
    BLOOD, 2018, 132
  • [47] Wnt5a Induces Interleukin-6 Via a ROR1-Dependent Pathway in Chronic Lymphocytic Leukemia, Leading to Leukemia-Cell Activation of STAT3
    Chen, Yun
    Chen, Liguang
    Yu, Jian
    Zhang, Ling
    Rassenti, Laura Z.
    Kipps, Thomas J.
    BLOOD, 2017, 130
  • [48] Restricted expression of the orphan tyrosine kinase receptor ROR1 in chronic lymphocytic leukemia
    Carson, DA
    Kipps, TJ
    BLOOD, 2004, 104 (11) : 221A - 221A
  • [49] Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo
    Liu, Zhuojun
    Liu, Jia
    Zhang, Tianming
    Shi, Mingxia
    Chen, Xiaofang
    Chen, Yun
    Yu, Jian
    PHARMACOLOGICAL RESEARCH, 2020, 151
  • [50] WNT5a/ROR1 axis in triple-negative breast cancer progression and potential therapy
    Borcherding, Nicholas
    Ameka, Magdalene
    Kolb, Ryan
    Xie, Qing
    Zhang, Weizhou
    CANCER RESEARCH, 2014, 74 (19)